Subscribe to eTOC



In November, George Karpati, MD, Isaac Walton Killam chair and professor of neurology at McGill University in Montreal, received the Prix Wilder Penfield in Biomedical Sciences Award for his outstanding research contributions in the diagnosis and treatment of neuromuscular disorders. The Prix Wilder Penfield is one of 11 Prix du Quebec awards (six cultural and five scientific) conferred annually by the Quebec government as the province's most prestigious recognitions for social and scientific advances.


Dr. George Karpati/

Dr. Karpati, who is senior neurologist and director of Neuromuscular Research at the Montreal Neurological Institute, is also a fellow of the Royal Society of Canada and a Knight of the Ordre National du Quebec. His research of clinical and basic studies on neuromuscular disorders includes diverse forms of molecular therapeutic strategies for Duchenne muscular dystrophy (DMD) and other types of dystrophies; metabolic myopathies; and glioblastoma.

Dr. Karpati's research team was the first to show the localization of dystrophin to the muscle fiber surface and to demonstrate a lack of dystrophin in muscle fibers of patients with DMD (Nature 1988;333:466–469). In 1990, he conducted the first controlled study of myoblast transfer in nine boys with DMD (Ann Neurol 1993;34:8–17).

The author of over 250 scientific research and review papers, Dr. Karpati has also edited or co-authored five books on the neuromuscular field. Currently Dr. Karpati is one of the primary investigators at the Centre of Excellence in Stem Cell Genomics and Therapeutics in the Canadian Networks of Centres of Excellence, where his research is dedicated to stem cell transfer for muscular dystrophies.

Timothy A. Pedley, MD, chairman of neurology and neurologist-in-chief at the Neurological Institute at Columbia University Medical Center in NYC, praised Dr. Karpati as one of the most distinguished members of the AAN. “The Prix du Québec honors Dr. Karpati's outstanding research contributions, and the AAN can take pride in this singular honor to one of its members.”


In November, Jeffrey L. Saver, MD, associate professor of neurology at the David Geffen School of Medicine at University of California-Los Angeles, UCLA, received the American Heart Association (AHA) Stroke Council Award for his research on stroke and his work promoting greater recognition of stroke in the cardiovascular community. The award was presented at the AHA Scientific Sessions Conference in Chicago.


Dr. Jeffrey L. Saver

Dr. Saver is chair of the AHA Stroke Council's Stroke Scientific Statement Oversight Committee.

Dr. Saver's research centers on the prevention, diagnosis, and treatment of stroke, as well as clinical trial design, neuroimaging, and neurocognitive and behavioral consequences of stroke. His work has been supported by grants from the NIH, the AHA, and the National Stroke Association. He has authored more than 80 original articles, more than 15 book chapters, and two edited volumes.

In September, Dr. Saver co-authored a study “to determine the frequency of early neurologic deterioration with infarct expansion and poor outcomes among ischemic stroke patients not treated with reperfusion therapies because of rapidly improving or mild symptoms.”

The study reported that 10 percent of patients “eligible for acute reperfusion therapy excluded on the basis of mild or rapidly improving symptoms show early neurologic deterioration with infarct expansion within 48 hours, and about 20 percent show poor outcome at discharge. Persisting large-vessel occlusion substantially increases the risk of early worsening and poor functional outcome” (Neurology 2006; 26;67(6):980–984).


Neurology Today's column, “Field Notes,” reports good news from the field – professional awards, promotions, or honors; new programs; appointments to national programs or committees; and recipients of large research grants; to name a few.

We want to hear from you.

Please send your items for consideration to: